Our preliminary data suggested to us a novel hypothesis that SK-2 generated S1P induces NSCLC growth via mediating hTERT/c-Myc oncogenic axis. As a corollary, we hypothesize that targeting SK-2/S1P induces hTERT degradation, leading to c-Myc inhibition and NSCLC tumor suppression without affecting telomere- replication function of hTERT. These novel hypotheses will be tested in two Specific Aims:
Aim 1. Determine the roles and mechanisms of SK-2/S1P in the regulation of hTERT stability.
Aim 2. Define the mechanisms by which SK-2/S1P regulates a non-canonical function of hTERT for c-Myc activation involved in controlling NSCLC tumor growth/proliferation. Data obtained from these studies will help dissect how SK2/S1P signaling is involved in selective regulation of a telomere-replication-independent (non-canonical) function of hTERT for, at least in part, inducing c-Myc oncogene, involved in NSCLC tumor growth and/or proliferation. Moreover, these studies will lead to the development of mechanism-based novel therapeutic strategies for improved NSCLC treatment to selectively inhibit oncogenic SK2/S1P/hTERT/c-Myc axis without affecting telomere-length regulation.

Public Health Relevance

The long-term goal of this proposal is to develop novel therapeutic strategies for the treatment of non-small cell lung cancers (NSCLC) via uncovering mechanisms involved in the regulation of non-canonical/telomere replication-independent functions of human telomerase reverse transcriptase (hTERT) by pro-survival sphingosine kinase-2/sphingosine 1-phosphate (SK-2/S1P) signaling for c-Myc oncogene activation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA088932-11A1
Application #
8514247
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Pelroy, Richard
Project Start
2000-12-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
11
Fiscal Year
2013
Total Cost
$205,662
Indirect Cost
$67,980
Name
Medical University of South Carolina
Department
Biochemistry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Dai, Lu; Plaisance-Bonstaff, Karlie; Voelkel-Johnson, Christina et al. (2014) Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells. PLoS One 9:e102314
Jiang, Wenhui; Ogretmen, Besim (2014) Autophagy paradox and ceramide. Biochim Biophys Acta 1841:783-92
Qin, Zhiqiang; Dai, Lu; Trillo-Tinoco, Jimena et al. (2014) Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 13:154-64
Saddoughi, Sahar A; Gencer, Salih; Peterson, Yuri K et al. (2013) Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 5:105-21
Saddoughi, Sahar A; Ogretmen, Besim (2013) Diverse functions of ceramide in cancer cell death and proliferation. Adv Cancer Res 117:37-58
Neviani, Paolo; Harb, Jason G; Oaks, Joshua J et al. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 123:4144-57
Meyers-Needham, Marisa; Ponnusamy, Suriyan; Gencer, Salih et al. (2012) Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells. EMBO Mol Med 4:78-92
Meyers-Needham, Marisa; Lewis, Jocelyn A; Gencer, Salih et al. (2012) Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther 11:1092-102
Senkal, Can E; Ponnusamy, Suriyan; Manevich, Yefim et al. (2011) Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated endoplasmic reticulum (ER) stress and apoptosis via perturbation of cellular Ca2+ and ER/Golgi membrane network. J Biol Chem 286:42446-58
Baran, Yusuf; Bielawski, Jacek; Gunduz, Ufuk et al. (2011) Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol 137:1535-44

Showing the most recent 10 out of 30 publications